evo101
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 27, 2022 (NCT05579899)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06645821 | Early Phase 1 (Phase 1) | Nov 30, 2024 | Evommune, Inc., Virginia Clinical Research, Inc. |
| NCT05579899 | Phase 2 | Sep 27, 2022 | Evommune, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Evommune, Inc. | For profit | 2 | 1 | 2 | 2022 |
| Virginia Clinical Research, Inc. | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1